Long-Term Outcomes of Endocrine Therapy in Breast Cancer

Overview of the Meta-Analysis

A comprehensive global meta-analysis of 88 clinical trials has shed light on breast cancer recurrence rates 5 to 20 years post endocrine therapy. This analysis highlights the efficacy of endocrine therapy, particularly in estrogen-receptor-positive patients, where it significantly diminishes the recurrence of breast cancer when administered as an adjuvant treatment for five years.

Extending Endocrine Therapy

There is evidence suggesting that prolonging adjuvant endocrine therapy beyond five years may further decrease the risk of recurrence. However, this extension is not without its challenges, as some women experience severe side effects, including life-threatening conditions such as pulmonary embolism and endometrial cancer. Notably, the probability of experiencing these serious side effects tends to rise with longer treatment durations.

Considerations for Treatment Duration

Deciding whether to extend endocrine therapy requires careful consideration of various factors. Researchers aimed to determine if the risk of breast cancer recurrence persists beyond the five-year mark following endocrine therapy.

Research Findings

Study Details

The meta-analysis, conducted by Hongchao Pan and colleagues in collaboration with the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), focused on the long-term outcomes of women with ER-positive, early-stage breast cancer who received adjuvant endocrine therapy. Their findings were published in the New England Journal of Medicine.

Patient Inclusion and Methodology

The study included over 62,000 women who were cancer-free five years after undergoing endocrine therapy. The results were categorized based on different trials and treatment regimens to analyze the relationship between tumor characteristics—such as diameter, nodal status, and grade—and patient outcomes over 5 to 20 years.

Key Results

The researchers uncovered several significant findings. The risk of recurrence during the 5 to 20-year period was notably linked to the initial nodal status of the tumor, with a steady increase in recurrence risk corresponding to higher nodal status. This trend was also observed in cases of contralateral breast cancer. Importantly, while the likelihood of recurrence within the first five years was minimal, the risk of cancer re-emerging elsewhere in the body from 5 to 20 years remained consistent.

Implications for Treatment Decisions

These findings underscore the association between nodal status and recurrence in patients with ER-positive breast cancer. The study suggests that patients should weigh the risks and benefits of continuing endocrine therapies beyond five years. However, it is important to note that the women included in this analysis were treated years, if not decades, ago when therapeutic options were less advanced. This raises the possibility that contemporary recurrence rates for women diagnosed with ER-positive breast cancer may be lower than those reported in this study.

Conclusion

The results of this meta-analysis provide critical insights into the long-term outcomes of endocrine therapy in breast cancer patients, emphasizing the need for individualized treatment decisions based on nodal status and potential risks.

Reference

Pan, H., Gray, R., Braybrooke, J., et al. 2017. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 377:1836-1846.